CAS: 826-39-1; N,2,3,3-Tetramethylbicyclo[2.2.1]Heptan-2-Amine Hydrochloride

该化合物是一种化学化合物,被归类为非选择性的尼基丁乙酰胆碱受体对抗物,主要用于治疗高血压,并在戒烟疗法中被调查其潜力.该物质看起来像白色的脱白晶粉,在水中溶解,便于其使用各种药物制剂.甲基胺通过阻塞乙酰胆碱在尼科提尼受体中的影响,导致同情性...

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    📜(+/-)-Mecamylamine 在 Sodium Ethanolate体系中,用 乙醇,氯仿作为反应溶剂,反应 1.0H,获得 (+/-)-Exo-Mecamylamine hydroChloride
    参考文献:通过(甲基苄基)脲类似物的热分解制备旋光性仲胺:(+)-和(-)-美甲胺的绝对构型.初步沟通† ‡
    标题:通过(甲基苄基)脲类似物的热分解制备旋光性仲胺:(+)-和(-)-美甲胺的绝对构型.初步沟通† ‡
    摘要:(+/-)-美甲胺((+/-)-1)的(α-甲基苄基)脲非对映异构体4和5和(+/-)-1-去甲甾氨酸o-甲基醚((+/-)-3)的6和7的热解.回流的醇除了可以循环利用的(α-甲基苄基)胺的光学纯氨基甲酸酯外,还以高收率提供了光学纯的胺.通过x射线衍射分析来确定(-)-甲酰胺胺盐酸盐((-)-1 .Hcl)的绝对构型.
    Doi:10.1002/Hlca.19860690205

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-2003138880-A1
    优先权日:2001-08-24
    标 题:Solid-phase synthesis of oligosaccharides and glycopeptides using glycosynthases
    发明人:WITHERS STEPHEN G; JENSEN KNUD J; PETERSEN LARS; TOLBORG JAKOB L
    权利人:UNIV BRITISH COLUMBIA
    摘要:The present invention provides materials and methods for the solid-phase synthesis of oligosaccharides and glycopeptides. Such materials and methods include mutant glycosidase enzymes, or “glycosynthases,â€? chemically-derivatized acceptor molecules, and specific solid support matrices.

    专利号:US-2008300418-A1
    优先权日:2004-11-08
    标 题:Synthesis of Cardiolipin Analogues and Uses Thereof
    发明人:AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
    权利人:AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
    摘要:The invention provides novel synthetic methodologies for preparing cardiolipin, migrated caridiolipin (1,2-positional isomer of cardiolipin) and their analogues having varying fatty acids and/or alkyl chains with varying length and degrees of saturation/unsaturation. The method comprises (a) reacting an optically pure 1,2-O-dialkyl-sn-glycerol or 1,2-O-dialkyl-sn-glycerol with one or more phosphoramidite reagent(s), wherein a phosphite triester is produced; (b) coupling the product of (a) with glycerol, wherein a protected cardiolipin is produced; and (c) deprotecting the protected cardiolipin, such that cardiolipin is prepared. The cardiolipins and analogues thereof, prepared by the present methods, can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs, antisense nucleotides or diagnostic agents. Such liposomes can be used to treat diseases or can be used in diagnostic and/or analytical assays.

    专利号:US-2006078560-A1
    优先权日:2003-06-23
    标 题 :Method of inducing apoptosis and inhibiting cardiolipin synthesis
    发明人:JAMIL HARIS; AHMAD MOGHIS U; AHMAD IMRAN
    权利人:NEOPHARM INC
    摘要:The present invention provides a method for inducing apoptosis within a cell by exposing the cell to an inhibitor of cardiolipin synthesis under conditions sufficient to induce apoptosis within the cell. The method can be used to investigate or treat disorders such as cancer, obesity, and cardiovascular disorders. The invention also provides a pharmaceutical composition including an inhibitor of cardiolipin synthesis and a liposomal carrier.

    专利号:US-2008286351-A1
    优先权日:2004-06-29
    标 题:Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof
    发明人:AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
    权利人:AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
    摘要:The invention provides synthetic methods for PEGylated cardiolipins with varying linkers. The methods can be employed to prepare PEGylated cardiolipin with different fatty acid and/or alkyl chain length with or without unsaturation. The PEGylated cardiolipin, prepared by the present methods, can be incorporated into liposomes that can also include active agents such as hydrophilic or hydrophobic drugs for the treatment of human and animal diseases. In addition, the PEGylated cardiolipin can be incorporated into liposomes that include compounds for therapeutic and diagnostic imaging. The use of such liposomes with PEGylated cardiolipin prolongs the period of liposomal circulation without disrupting the lipid bilayer.

    专利号:US-2005266068-A1
    优先权日:2002-05-24
    标题 :Cardiolipin molecules and methods of synthesis
    发明人:AHMAD MOGHIS U; UKKALAM MURALI K; AHMAD IMRAN
    权利人:NEOPHARM INC
    摘要:The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation, particularly a short-chain cardiolipin. The methods comprise reacting a 1,2-O-sn-diacyl/1,2-O-sn-dialkyl glycerol or a 2-O-protected glycerol, with a phosphoramidite reagent or a phosphate triester to produce a protected cardiolipin, which is deprotected to prepare the short chain cardiolipin. The reaction schemes can be used to generate new variants of cardiolipin. The cardiolipin prepared by the present methods can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs. Such liposomes can be used to treat diseases or in diagnostic and/or analytical assays. Liposomes can also include ligands for targeting a particular cell type or specific tissue.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Nickell JR, Grinevich VP, Siripurapu KB, Smith AM, Dwoskin LP. Potential therapeutic uses of mecamylamine and its stereoisomers. Pharmacol Biochem Behav. 2013 Jul;108:28-43. doi: 10.1016/j.pbb.2013.04.005. Epub 2013 Apr 18. Review.
    2: Kirshenbaum AP, Jackson ER, Brown SJ, Fuchs JR, Miltner BC, Doughty AH. Nicotine-induced impulsive action: sensitization and attenuation by mecamylamine. Behav Pharmacol. 2011 Jun;22(3):207-21. doi: 10.1097/FBP.0b013e328345ca1c.
    3: Elrashidi MY, Ebbert JO. Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opin Emerg Drugs. 2014 Jun;19(2):243-60. doi: 10.1517/14728214.2014.899580. Epub 2014 Mar 22. Review. Review. doi: 10.1586/14737175.2016.1135735. Epub 2016 Jan 14. Review. doi: 10.1016/j.bbr.2015.10.044. Epub 2015 Oct 28. doi: 10.1016/j.ejphar.2015.04.002. Epub 2015 Apr 9. Minn Med. 1958 Jul;41(7):499-502. Spanish. English, Italian. Italian.

    合成参考文献


    摘要:Research Progress in Organic-Biological and Medicinal Chemistry., 2(301), 1970
    摘要:Journal of Pharmacology and Experimental Therapeutics., 117(169), 1956 []
    参考文献:10.1007/s00441-006-0226-0
    摘要:Sweeney WE, Avner ED. Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD). Cell Tissue Res. 2006 Dec;326(3):671–85. doi: 10.1007/s00441-006-0226-0.
    参考文献:10.1007/s00467-006-0142-2
    摘要:Finer G, Shalev H, Landau D. Genetic kidney diseases in the pediatric population of southern Israel. Pediatr Nephrol. 2006 Jul;21(7):910–6. doi: 10.1007/s00467-006-0142-2.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知